It has been hypothesized that a subgroup of patients with a worse prognosis may benefit from the addition of an MEK inhibitor, particularly those with a higher BRAF-mutant allele fraction in circulating tumor DNA31 or tumor tissue,13 or those classified under the CMS4 or BM1 subgroups based on transcriptome analysis.32 The gene discussed is BRAF; the disease is neoplasm.